GLG News by Lung Cancer Oncologists (EU)

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Cost will be the tricky point...

August 22, 2009

IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

I believe that, considering the other available agents, gefitinib could be prescribed to up to 1/3 of NSCLC patients...

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Another option in NSCLC...?!?

July 2, 2009

IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.  

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Iressa: will it be a new therapeutic option or will it replace another existing option?

May 4, 2009

IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

The recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommending to grant a marketing authorisation for Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Another good result for Roche.

March 23, 2009

UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com

The results from ToGA, a large international phase III trial, showed the benefit of herceptin plus chemotherapy vs chemotherapy alone as the first therapy for patients with advanced unresectable gastric cancer.  

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

A Novel Option for Management of Malignant Ascites.

March 23, 2009

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: SUMMARY OF POSITIVE OPINION FOR REMOVAB | www.emea.europa.eu

Catumaxomab is a trifunctional monoclonal antibody with 2 antigen-recognition sites: one for human EpCAM, a cell surface antigen expressed by a variety of epithelial tumor cells, and one for human CD3, a T-cell surface antigen. In addition, another region of the antibody binds to receptors that are expressed on other cells of the immune system.

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

The nth proof...

February 16, 2009

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer | www.ncbi.nlm.nih.gov

The trial showed that the addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. This is a new demonstration that the association of anti-EGFR and anti-angiogenic drugs is toxic and ineffective. 

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Each Country is different...

February 9, 2009

Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs | content.nejm.org

The cost for cancer drugs is increasing, but big differences among the different Countries are present.

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Are nexavar prescriptions increasing?

February 9, 2009

Nexavar® Effective for Hepatocellular Carcinoma in Asians | patient.cancerconsultants.com

Nexavar confirms its efficacy for hepatocellular carcinoma also in the Asian population.

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

E-prescriptions are not available in all the Countries.

February 9, 2009

Incentives Push More Doctors to E-Prescribe | online.wsj.com

In Italy e-prescription is well away from being available.

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

It is not so terrible, but...

February 2, 2009

Eli Lilly reports 4Q loss on ImClone costs | finance.yahoo.com

Obviously Lilly will survive and the situation is not so terrible, but  in oncology at least in Europe...

Page : 12Next1 to 10 of 16

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News